Results 41 to 50 of about 4,214,171 (152)

Synthesis and Biological Evaluation of ^99mTc(I) Tricarbonyl Complexes Dual-Targeted at Tumoral Mitochondria

Molecules, 2021
For effective Auger therapy of cancer, the Auger-electron emitters must be delivered to the tumor cells in close proximity to a radiosensitive cellular target.
Diogo Figueiredo, Célia Fernandes, Francisco Silva, Elisa Palma, Paula Raposinho, Ana Belchior, Pedro Vaz, António Paulo   +7 more
doaj   +1 more source

In Situ Self‐Assembled Molecular Fortifying Agent for Enhanced Retention and Therapeutic Efficacy of Radiopharmaceuticals

Aggregate, Volume 7, Issue 10, October 2026.
A molecular‐fortifying agent strategy based on in situ self‐assembly is developed to prolong tumor retention of radioligands. After tumor‐targeting, FAP‐α cleavage triggers nanofiber formation, presenting azide anchors for bioorthogonal capture of pre‐accumulated radioligands.
Daojia Liu, Xiaoqin Luo, Xiaojuan Wang, Xing Liu, Fanglei Zhang, Pan Wang, Jibin Song, Junqiang Chen   +7 more
wiley   +1 more source

Nanomaterial‐Mediated Radiotherapy–Immunotherapy Combinations: Breaking Immunosuppression and Revolutionizing Cancer Treatment

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
Nanomaterials integrate radiotherapy and immunotherapy by enhancing radiosensitivity, remodeling the immunosuppressive tumor microenvironment, and promoting systemic antitumor immunity. This review summarizes the latest strategies of nanomaterial‐mediated combinations (RT, immunotherapy, IRT) and highlights future directions for overcoming clinical ...
Peijie Li, Xiangqin Wang, Sisi He, Hu Ma
wiley   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

Dual targeting with 224Ra/212Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach

Frontiers in Medicine, 2023
Metastases are the primary cause of death among cancer patients and efficacious new treatments are sorely needed. Targeted alpha-emitting radiopharmaceuticals that are highly cytotoxic may fulfill this critical need.
Asta Juzeniene, Asta Juzeniene, Vilde Yuli Stenberg, Vilde Yuli Stenberg, Vilde Yuli Stenberg, Øyvind Sverre Bruland, Øyvind Sverre Bruland, Mona-Elisabeth Revheim, Mona-Elisabeth Revheim, Roy Hartvig Larsen   +9 more
doaj   +1 more source

Feasibility of convection‐enhanced delivery of unlabeled 225Ac for glioblastoma: Transport, dosimetry, and clonogenic survival modeling

Medical Physics, Volume 53, Issue 8, August 2026.
Abstract Background Glioblastoma (GB) is an aggressive primary brain tumor with local recurrence rates exceeding 90% and a five‐year survival rate of approximately 5%. Standard treatments such as surgical resection, external beam radiotherapy (EBRT), and chemotherapy often leave residual tumor cells that are resistant to therapy.
Maram El Sabri, Leyla Moghaddasi, Puthenparampil Wilson, Frank Saran, Eva Bezak   +4 more
wiley   +1 more source

A new perspective on radiotherapy in the comprehensive treatment of cancer

Precision Radiation Oncology, Volume 10, Issue 2, Page 165-183, June 2026.
Radiotherapy remains a key component in the comprehensive management of cancer. Its effectiveness is significantly improved through strategic combinations with chemotherapy, targeted therapy, and immunotherapy, providing a range of therapeutic outcomes from cure to palliative care.
Yingze Ma, Hongxuan Yu, Shijie Shang, Shixin Shan, Dawei Chen   +4 more
wiley   +1 more source

Ultrasmall Au10–12 Nanoclusters: A Novel Platform for 223Ra‐Targeted Tumor α‐Therapy

Exploration, Volume 6, Issue 2, April 2026.
Encapsulating 223Ra in Au10‐12 nanoclusters and functionalizing them with RGD peptides enables targeted α‐therapy and immune microenvironment remodeling in non‐osseous tumors like triple‐negative breast cancer. This study establishes a foundational framework for novel 223Ra‐labeled α‐radiopharmaceuticals and shows strong potential for clinical ...
Yifei Jiang, Huizhen Yang, Guoping Jia, Wangxi Hai, Rongyi Huang, Peng Wang, Min Zhang, Danni Li, Yizhou Chen, Xiao Li, Biao Li, Chunfu Zhang   +11 more
wiley   +1 more source

Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management

ChemBioChem, Volume 27, Issue 1, January 2026.
Radiopharmaceuticals enable precise cancer diagnosis and targeted therapy by combining radioactive isotopes with carrier molecules. This review summarizes advances from 2014 to 2025, emphasizing probe design, click chemistry, novel targets, and nanodelivery systems.
Mohd Sayeed Shaikh, Rupesh R. Kurhade, Abrar A. M. Siddiqui, Shaikh Shahbaz A. Majeed, Thomas J. Webster, Mohammad Intakhab Alam, Abdul Wasy Zia, Md. Faiyazuddin   +7 more
wiley   +1 more source

Targeted radionuclide therapy in combined-modality regimens [PDF]

, 2017
Targeted radionuclide therapy (TRT) is a branch of cancer medicine concerned with the use of radioisotopes, radiolabelled molecules, nanoparticles or microparticles that either naturally accumulate in or are designed to home to tumours.
Yong Du, Martin R Gill, Katherine A Vallis, Nadia Falzone, Martin Gill   +4 more
core   +1 more source